glp 1 oral drugs New GLP-1 Outperforms Semaglutide glp-1 oral dosage for weight

This analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for GLP-1s

Both compounds reduce liver fat, but mazdutide provides strong hepatic benefits through its glucagon component without the additional gastrointestinal burden of triple agonism

[13] In the other five trials (NCT01930188, [69] NCT01885208, [70] NCT02128932, [71] NCT02207374, [72] and NCT02254291 [73] ), participants were randomly assigned to receive either semaglutide or another anti-diabetic medication, and the participant and provider knew which medication was being given in four trials

2.Valenzuela PL, Carrera-Bastos P, Castillo-Garca A, Lieberman DE, Santos-Lozano A, Lucia A (2023) Obesity and the risk of cardiometabolic diseases